Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27712641 | 0.85 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL30639497 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL3602439 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL1936414 | 0.77 | P4HTM (0.48) | ACACB | |
| SCHEMBL1390470 | 0.77 | ACACB (0.45) | ACACBCHRNB2CHRNA4 | |
| SCHEMBL82719 | 0.76 | PDE10A (0.46) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL256028 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL10187966 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL2228978 | 0.74 | PIK3CA (0.49) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL19120462 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102145-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013102145-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PIK3CD 4000/4885PIK3CA 3340/4885PIK3CB 2897/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PIK3CD 4000/4885PIK3CA 3340/4885PIK3CB 2897/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PIK3CD 4000/4885PIK3CA 3340/4885PIK3CB 2897/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PIK3CD 4000/4885PIK3CA 3340/4885PIK3CB 2897/4885 |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | PIK3CD 3854/4885PIK3CA 3884/4885PIK3CB 2948/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PIK3CD 4000/4885PIK3CA 3340/4885PIK3CB 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.